Back

Symptomatic hypotension and worsening renal function according to guideline directed medical therapy levels in high-risk heart failure patients.

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - treatment 7 Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Professor Nathan Mewton

Civils Hospices of Lyon, Lyon (France)

7 More presentations in this session

Presentation thumbnail
A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.
Doctor R. Mathur (Jodhpur, IN)
Abstract Slides Video
Presentation thumbnail
Optimization of pharmacological treatment of heart failure in patients followed in specialized HF units in Spain.
Doctor R. Gonzalez-Manzanares (Cordoba, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Characteristics of patients initiating dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice: a 6-month interim analysis of EVOLUTION-HF Italy
Associate Professor P. Ameri (Genova, IT)
Abstract Slides Video
Presentation thumbnail
Asymptomatic versus symptomatic hypotension in HFrEF: Findings with sacubitril/valsartan in PARADIGM-HF
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - treatment 7

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Titration of guideline directed medical therapy in a high-risk heart failure patients and impact on heart failure events
thumbnail
Congress Presentation
Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy
thumbnail
Congress Presentation
Impact of GDMT implementation on albuminuria in HFrEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources